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Introduction
Utilization of low-dose computed tomography (CT) lung can-
cer screening (LCS) remains low despite demonstrated effica-
cy, clinical recommendation, and insurance coverage [1, 2]. In
2015, only 3.9% of screening-eligible persons reported CT
LCS within the past year [3]. Screening rates may be low for
several reasons. First, patients may not seek screening due to
lack of knowledge. Second, healthcare providers may lack a
detailed understanding of the potential benefits and harms of
CT LCS and, therefore, fail to initiate conversations with their
patients.We undertook this study to estimate the prevalence of




This study utilized data from the Health Information National
Trends Survey (HINTS), a nationally representative, cross-
sectional survey administered by the US National Cancer
Institute to evaluate the use of cancer-related information.
HINTS 5, Cycle 1 data (N = 3285) were collected from
January–May 2017 and utilized a two-stage sampling design.
This study focused on 1667 respondents whose age fell within
the USPSTF recommended age interval for LCS (55–
80 years).
Outcome and Covariates
The outcome was past-year discussion with a healthcare
provider about LCS (BAt any time in the past year, have
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Abstract
Computed tomography lung cancer screening reduces lung cancer mortality. However, screening is underutilized. This study 
assesses the extent to which providers discuss lung cancer screening with their patients, as a lack of discussion and counseling 
may serve as a potential cause of low utilization rates. Data from 1667 adults aged 55–80 years sampled in the 2017 Health 
Information National Trends Survey was utilized. A weighted multivariable logistic regression model was fit with past-year 
discussion about lung cancer screening with a provider as the outcome. The adjusted odds of discussion were higher for current 
cigarette smokers compared to non-cigarette smokers (adjusted odds ratio = 3.91; 95% confidence interval [CI], 1.75 to 8.74). 
Despite higher odds, the absolute prevalence was low with only 18% (95% CI, 11.8 to 24.2%) of current adult smokers reporting 
a past-year discussion. Knowledge of screening from trusted sources of medical information, such as doctors, can increase 
screening rates and may ultimately reduce lung cancer mortality.
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you talked with your doctor or other health professional
about having a test to check for lung cancer?^). Socio-
demographic characteristics included age, race/ethnicity,
and education. Health-related characteristics included
self-reported health, history of cancer, certain comorbid-
ities (diabetes, hypertension, heart condition, and chron-
ic lung disease), regular source of care, and health in-
surance status. Smoking status included never, former,
and current cigarette smokers. Level of trust in informa-
tion about health or medical topics was categorized as a
lot, some, a little, or none and was assessed from var-
ious sources, including the government, family, and a
doctor or other healthcare professional (hereafter,
Bprovider^). See Supplementary Table 1 for details.
Analysis
First, the level of trust about health information from providers
was compared to the corresponding level of trust from other
sources. Second, the prevalence of discussions with providers
about LCS within the past year was estimated by smoking
status. Third, a weighted multivariable logistic regression
model was fit with past-year LCS discussion as the outcome;
covariates included socio-demographic and health character-




The percentage of the population aged 55–59, 60–64, 65–69,
and 70–80 years were 27.4%, 24.5%, 20.5%, and 27.6%, re-
spectively. The population was 48.1% male; 76.4% non-
Hispanic white, 8.6% non-Hispanic black, and 9.2%
Hispanic; and 96.1% had health insurance (Table 1). The per-
centage of never, former, and current cigarette smokers were
52.4%, 32.8%, and 14.8%, respectively. Most respondents
reported their health as either very good (33.8%) or good
(35.8%). Hypertension was commonly reported (58.1%),
whereas chronic lung disease and a heart condition were less
frequently reported (15.5% and 12.9%, respectively).
Trust Information about Health or Medical Topics
Providers were the most trusted source of information
(Supplementary Fig. 1). For example, 70.5% of adults report-
ed that they would trust information about health or medical
topics from a provider Ba lot^ compared to only 21.8% of
adults reporting this same level of trust if the source of infor-
mation was the government.
Lung Cancer Screening by Cigarette Smoking Status
Eighteen percent of current cigarette smokers reported a discus-
sion with their provider about LCS within the past year (95%
CI, 11.8 to 24.2%; Fig. 1). Discussion prevalence was lower for
former cigarette smokers (10.5%; 95% CI, 7.3 to 13.8%) and
never cigarette smokers (3.8%; 95% CI, 2.1% to 5.6%).
Table 1 Characteristics of study population
N Wgt. Prev. 95% CI
Age group (years)
55–59 374 27.4% (24.3%, 30.6%)
60–64 404 24.5% (21.6%, 27.4%)
65–69 412 20.5% (18.0%, 22.9%)
70–80 477 27.6% (24.7%, 30.5%)
Sex
Male 705 48.1% (44.8%, 51.5%)
Female 938 51.9% (48.5%, 55.2%)
Race/ethnicity
Non-Hispanic White 1046 76.4% (73.6%, 79.2%)
Non-Hispanic Black 196 8.6% (6.8%, 10.4%)
Hispanic 160 9.2% (7.3%, 11.2%)
Non-Hispanic Asian 54 3.1% (2.0%, 4.2%)
Non-Hispanic Other 54 2.8% (1.7%, 3.8%)
Educational attainment
Less than high school 121 8.9% (6.6%, 11.2%)
High school graduate 373 27.6% (24.6%, 30.5%)
At least some college 1161 63.5% (60.2%, 66.8%)
Health insurance coverage 1591 96.1% (94.7%, 97.5%)
Cigarette smoking status
Never 907 52.4% (49.1%, 55.8%)
Former 528 32.8% (29.7%, 35.9%)
Current 224 14.8% (12.1%, 17.4%)
Regular healthcare provider 1647 78.6% (75.8%, 81.5%)
Self-reported health
Excellent 160 8.9% (7.1%, 10.6%)
Very good 559 33.9% (30.8%, 37.1%)
Good 594 35.8% (32.6%, 38.9%)
Fair 291 18.1% (15.4%, 20.7%)
Poor 49 3.4% (2.0%, 4.7%)
Ever had cancer 1664 16.9% (14.7%, 19.0%)
Diabetes 1639 15.5% (12.8%, 18.2%)
Heart condition 1643 12.9% (10.7%, 15.2%)
Chronic lung disease 1635 58.1% (54.8%, 61.4%)
Body mass index
Underweight 16 0.7% (0.3%, 1.1%)
Normal 423 26.1% (23.1%, 29.0%)
Overweight 583 35.3% (32.1%, 38.5%)
Obese 602 37.9% (34.6%, 41.2%)
N, count; Wgt. Prev., weighted prevalence; CI, confidence interval
Correlates of Lung Cancer Screening Discussion
The odds of discussing LCS with a provider within the past
year were higher for current (adjusted odds ratio [aOR] = 3.91;
95% CI, 1.75 to 8.74) and former (aOR = 2.06; 95% CI, 1.10
to 3.86) cigarette smokers compared to never cigarette
smokers (Table 2). Odds of discussion were also higher for
adults aged 65–69 years compared to adults aged 55–59 years
(aOR = 2.81; 95% CI, 1.24 to 6.36), those who ever had can-
cer (aOR = 1.99; 95% CI, 1.14 to 3.47), and those with chron-
ic lung disease (aOR = 3.02 95% CI, 1.63 to 5.61). Odds of
discussion were not significantly higher for adults with health
insurance compared to those without (aOR = 1.48; 95% CI,
0.28 to 7.95).
Discussion
Our study suggests the low prevalence of discussions about
LCS between patients and providers may partly explain the
low prevalence of CT LCS. Several barriers may prevent these
discussions, including confusion about eligibility criteria, lack
of sufficient time during a routine office visit, and discomfort
with managing screen-detected findings [4]. Even when con-
versations do occur, they may be poor in quality [5]. A recent
qualitative analysis of conversations between providers and
patients about LCS concluded these discussions frequently
scored low on a validated scale of shared decision making,
rarely discussed potential harms, and did not utilize patient
education materials, despite evidence that they help patients
reach an informed decision [6, 7]. More rigorous training for
providers in shared decision-making—a Centers for Medicare
and Medicaid Services requirement of LCS—could improve
discussion quality [8].








Fig. 1 Prevalence of discussion
with doctor or other healthcare
professional about lung cancer
screening within past year by
cigarette smoking status. Source:
Authors’ analysis of 2017 Health
Information National Trends
Survey 5, Cycle 1
Table 2 Weighted multivariable logistic regression results: discussion
with doctor or other healthcare professional about lung cancer screening
within past year
Covariate Adj. OR (95% CI)
Age group (ref: 55–59 years)
60–64 1.51 (0.62, 3.67)
65–69 2.81 (1.24, 6.36)
70–80 1.43 (0.62, 3.29)
Female (ref: male) 0.58 (0.32, 1.05)
Race/ethnicity (Ref: Non-Hispanic White)
Non-Hispanic Black 1.45 (0.58, 3.60)
Hispanic 1.01 (0.36, 2.84)
Non-Hispanic Asian 2.50 (0.70, 8.91)
Non-Hispanic Other 2.45 (0.70, 8.51)
Educational attainment (ref: < high school)
High school graduate 0.38 (0.09, 1.57)
At least some college 0.34 (0.09, 1.33)
Health insurance (ref: no) 1.48 (0.28, 7.95)
Smoking status (ref: never)
Current 3.91 (1.75, 8.74)
Former 2.06 (1.10, 3.86)
Trust information from a doctor1 (ref: not at all)
A lot 0.55 (0.04, 7.95)
Some 0.92 (0.06, 13.66)
A little 0.32 (0.02, 6.35)
Regular healthcare provider (ref: no) 1.48 (0.64, 3.41)
Self-reported health (ref: good)
Excellent 0.38 (0.10, 1.44)
Very good 1.03 (0.56, 1.90)
Fair 0.59 (0.28, 1.24)
Poor 1.03 (0.29, 3.68)
Ever had cancer (ref: no) 1.99 (1.14, 3.47)
Diabetes 1.23 (0.65, 2.31)
Heart condition 1.09 (0.52, 2.31)
Hypertension 0.94 (0.51, 1.72)
Chronic lung disease 3.02 (1.63, 5.61)
Body mass index (ref: normal)
Underweight 1.57 (0.21, 11.64)
Overweight 0.82 (0.41, 1.65)
Obese 0.82 (0.39, 1.73)
Adj. OR, adjusted odds ratio; CI, confidence interval; Ref, reference
1 Trust information about health or medical topics from a doctor or other
healthcare professional
Better patient engagement could increase the frequency and
quality of discussions. Patients interested in LCS may not fully
comprehend existing educational materials because they are
written at exceedingly high readability levels [9]. Professional
medical societies could address this current gap by producing
educational materials written at an appropriate reading level.
We note several limitations. First, the data collected in
HINTS did not allow us to estimate pack-year smoking histo-
ry and, therefore, screening eligibility under USPSTF recom-
mendations. However, in 2017, 41.6% of current smokers
aged 55–80 years were ≥ 30 pack-year smokers and another
19.9% were 20–29 pack-year smokers (Supplementary
Fig. 2). Current smokers with 20–29 pack-year smoking
histories—included in our analysis—may also benefit from
CT LCS [10]. Second, HINTS did not specify the modality
of screening. Some physicians may have discussed chest X-
ray screening even though it is not clinically recommended.
Thus, our study may conservatively estimate the prevalence of
discussion between physicians and patients on CT LCS.
An important precursor to patients receiving routine CT
LCS is knowledge and awareness. Providers often serve as
trusted sources of information, and discussions that appropri-
ately explain potential risks and benefits can help increase
awareness and deliver patient-centered care. If these discus-
sions encourage high-risk patients to screen routinely, the bur-
den of lung cancer mortality may decrease.
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